Aller au contenu
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Langue
Tous les champs
Titre
Auteur
Sujet
Cote
ISBN/ISSN
Tag
Rechercher
Recherche avancée
Risk factors for fatal and non...
Citer
Envoyer par SMS
Envoyer par courriel
Imprimer
Exporter les notices
Exporter vers RefWorks
Exporter vers EndNoteWeb
Exporter vers EndNote
Permalien
Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
Détails bibliographiques
Auteurs principaux:
Mcmurray, J
,
Laakso, M
,
Standl, E
,
Tognoni, G
,
Holman, R
,
Giles, T
,
Martinez, F
,
Thomas, L
,
Haffner, S
,
Califf, R
Format:
Journal article
Publié:
2011
Exemplaires
Description
Documents similaires
Affichage MARC
Description
Résumé:
Documents similaires
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
par: Preiss, D, et autres
Publié: (2013)
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
par: Preiss, D, et autres
Publié: (2012)
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
par: Califf, R, et autres
Publié: (2008)
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
par: Krum, H, et autres
Publié: (2010)
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
par: Latini, R, et autres
Publié: (2013)